Posted by Michael Wonder on 04 Dec 2022
PHARMAC seeking feedback on funding Trikafta
4 December 2022 - PHARMAC has reached a provisional agreement with medicine supplier Vertex to fund Trikafta.
“Following our budget increase in May 2022 and commercial negotiations with the supplier, Vertex, I am thrilled to announce today that we are initiating consultation on the funding of Trikafta for people aged 6 years and above with cystic fibrosis who meet certain eligibility criteria,” says PHARMAC’s director of operations Lisa Williams.
